A Randomized, Double Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 21 May 2014

At a glance

  • Drugs Toremifene (Primary)
  • Indications Fracture; Male osteoporosis; Prostate cancer; Vertebral fracture
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms TREAT-1
  • Sponsors GTx
  • Most Recent Events

    • 01 Feb 2014 Results of an analysis of free serum testosterone levels at baseline in men who had undergone orchiectomy (n=114) presented at the 2014 Genitourinary Cancers Symposium.
    • 09 Jun 2010 Results of this trial have been presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010), according to a GTx media release.
    • 28 May 2010 Additional study results of a substudy evaluating PSA progression-free survival will be presented at the American Urological Association Annual Meeting, according to a GTx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top